KBI Biopharma

North America, North Carolina, United States, Durham

Description

KBI Biopharma, Inc. (KBI) is a leading development and contract manufacturing organization serving the biopharmaceutical industry. We help

Investor Profile

KBI Biopharma has made 5 investments, with 0 in the past 12 months and 60% as lead.

Stage Focus

Series D (40%)
Series A (40%)
Seed (20%)

Country Focus

United States (80%)
Ireland (20%)

Industry Focus

Biotechnology
Life Science
Artificial Intelligence (Ai)
Biopharma
Therapeutics
Medical
Health Care
Health Diagnostics

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does KBI Biopharma frequently co-invest with?

Phoenix Venture Partners

North America, California, United States, San Mateo

Co-Investments: 2

Novartis Venture Fund

Europe, Basel-Stadt, Switzerland, Basel

Co-Investments: 1

UT Horizon Fund

North America, Texas, United States, Austin

Co-Investments: 1

Oregon Venture Fund

North America, Oregon, United States, Portland

Co-Investments: 1

Enterprise Ireland

Europe, Dublin, Ireland, Dublin

Co-Investments: 1

WRF Capital

North America, Washington, United States, Seattle

Co-Investments: 1

JSR

Asia, Tokyo, Japan, Tokyo

Co-Investments: 1

Columbia Ventures Corporation

North America, Washington, United States, Vancouver

Co-Investments: 1

Lilly Ventures

North America, Indiana, United States, Indianapolis

Co-Investments: 1

JSR Life Sciences

North America, California, United States, Sunnyvale

Co-Investments: 1

What are some of recent deals done by KBI Biopharma?

Absci

Vancouver, Washington, United States

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI)BiopharmaBiotechnologyLife Science

Series DJan 14, 2020

Amount Raised: $10,400,000

Absci

Vancouver, Washington, United States

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI)BiopharmaBiotechnologyLife Science

Series DJan 7, 2019

Amount Raised: $10,360,013

Comera Life Sciences

Woburn, Massachusetts, United States

Comera Life Sciences Holdings is an engineering superior biotherapeutic formulations for fragile patients.

BiotechnologyHealth DiagnosticsTherapeutics

Series AApr 4, 2018

GlycoSeLect

Dublin, Dublin, Ireland

GlycoSeLect specializes in the development of technology to separate glycoproteins for biopharmaceutical product analysis & manufacture.

BiotechnologyLife ScienceMedical

SeedOct 24, 2017

Amount Raised: $529,203

Aeglea BioTherapeutics

Austin, Texas, United States

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

BiotechnologyHealth CareTherapeutics

Series AFeb 6, 2014

Amount Raised: $12,000,000

KBI Biopharma

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does KBI Biopharma frequently co-invest with?

What are some of recent deals done by KBI Biopharma?

Ready to Raise Capital?

Pages

Free tools